Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 272
- Registration Number
- NCT06102395
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, Beijing, China
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Beijing Tongren Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT06100497
- Locations
- 🇨🇳
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing, Beijing, China
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
- Conditions
- Interventions
- First Posted Date
- 2023-10-24
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06097728
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- AbbVie
- Registration Number
- NCT06093503
Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-12-07
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06095141
- Locations
- 🇨🇳
Shanghai Cancer Center, Shanghai, China
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1
- Registration Number
- NCT06094296
- Locations
- 🇺🇸
Local Institution - 0058, Boise, Idaho, United States
🇺🇸Local Institution - 0044, Clermont, Florida, United States
🇺🇸Local Institution - 0049, Houston, Texas, United States
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06091124
- Locations
- 🇨🇳
Ren Ji Hospital, Shanghai, Shanghai, China
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
- Conditions
- Oropharyngeal Squamous Cell CarcinomaStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8Stage III Hypopharyngeal Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8Head and Neck Squamous Cell CarcinomaLaryngeal Squamous Cell CarcinomaOral Cavity Squamous Cell CarcinomaStage IV Laryngeal Cancer AJCC v8
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinProcedure: Chest RadiographyDrug: CisplatinProcedure: Computed TomographyRadiation: Image Guided Radiation TherapyRadiation: Intensity-Modulated Radiation TherapyProcedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyDrug: Xevinapant
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Registration Number
- NCT06084845
Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Target Recruit Count
- 72
- Registration Number
- NCT06081673
- Locations
- 🇨🇳
Shanghai Ninth People's Hostipal, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-10-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT06077500
- Locations
- 🇪🇸
Hospital Virgen Macarena, Sevilla, Spain
🇧🇪Kortrijk - HOSP AZ Groeninge Kennedylaan, Kortrijk, Belgium
🇫🇷INS Bergonie, Bordeaux, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.